Primary Sjögren syndrome in primary health care

Sjogren's Syndrome: Diagnosis and Therapeutics

Volumn , Issue , 2012, Pages 501-514

  Sisó Almirall, Antoni ^a   Benavent, Jaume ^a   Bosch, Xavier ^b   Bové, Albert ^b   Ramos Casals, Manuel ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865774767     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-85729-947-5_35     Document Type: Chapter

References (43)

1. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren’s syndrome. Autoimmunity Reviews 2010;9:A305-A310.
2. Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain. Clinical and immunologic expression in 1010 patients. Medicine. 2008;87:210-9.
3. Lawn JE, Rohde J, Rifkin S, et al. Alma-Ata 30 years on: revolutionary, relevant, and time to revitalise. Lancet. 2008;372(9642):917-27.
4. Sisó A, Aymamí A, Campoy A, et al. Síndrome de Sjögren primario: ?Una entidad infradiagnosticada por el Médico de Familia? 18º Congreso Nacional de la Sociedad Española de Medicina Familiar y Comunitaria. Zaragoza 1998. Aten Primaria. 1998;22 Suppl 1:390.
5. Allen J, Gay B, Crebolder H et al. The European definitions of general practice/family medicine. The key features of the discipline of general practice. EURACT 2005 (2005). Available in http://www.euract.org/index.php?folder_id=25 Accessed Date: [11-October-2010].
6. Kassan SJS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med. 2004;164:1275-84.
7. Sorlí JV, Doménech IE, Zurián FJ, et al. Sjögren syndrome. Aten Primaria. 2009;41(7): 417-9.
8. Fox RI. Sjogren’s syndrome. Lancet. 2005;366:321-31.
9. Al-Hashimi I. The management of Sjogren’s syndrome in dental practice. J Am Dent Assoc. 2001;132:1409-17.
10. Caffery B, Simpson TL, Wang S, et al. Rose bengal staining of the temporal conjunctiva differentiates Sjögren’s syndrome from keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2010;51(5):2381-7.
11. García-Carrasco M, Ramos-Casals M, Rosas J, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine. 2002;81:270-80.
12. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren’s syndrome. Semin Arthritis Rheum. 2000;29:296-304.
13. Fox PC, Bowman SJ, Segal B, et al. Oral involvement in primary Sjögren syndrome. J Am Dent Assoc. 2008;139:1592-601.
14. Belenguer R, Ramos-Casals M, Brito-Zeron P, et al. Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2005;23:351-6.
15. Ostuni P, Botsios C, Sfriso P, et al. Prevalence and clinical features of fibromyalgia in systemic lupus erythematosus, systemic sclerosis, and Sjögren’s syndrome. Minerva Med. 2002;93:203-9.
16. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjogren’s syndrome. Results of a prospective concerted action supported by the European community. Arthritis Rheum. 1993;36:340-7.
17. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-8.
18. Ramos-Casals M, Brito-Zerón P, Pérez-de-Lis M, et al. Sjögren syndrome or Sjögren disease? the histological and immunological bias caused by the 2002 criteria. Clin Rev Allergy Immunol. 2010;38(2-3):178-85.
19. Rosas J, Ramos-Casals M, Ena J, et al. Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjogren’s syndrome. Correlation with clinical, immunological and histological features. Rheumatology. 2002;41:670-5.
20. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum. 2004;50:1262-9.
21. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum. 2002;46:741-7.
22. Ramos-Casals M, Brito-Zeron P, Yague J, Akasbi M, Bautista R, Ruano M, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren’s syndrome. Rheumatology (Oxford). 2005;44:89-94.
23. Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Primary Sjogren syndrome: hematologic patterns of disease expression. Medicine. 2002;81:281-92.
24. Brito-Zeron P, Ramos-Casals M, Nardi N, et al. Circulating monoclonal immunoglobulins in Sjogren syndrome: prevalence and clinical significance in 237 patients. Medicine. 2005;84: 90-7.
25. Pérez-de-Lis M, Akasbi M, Sisó A, et al. Cardiovascular risk factors in primary Sjögren’s syndrome: a case-control study in 624 patients. Lupus. 2010;19(8):941-8.
26. Kang JH, Lin HC. Comorbidities in patients with primary Sjögren’s Syndrome: a registrybased case-control study. J Rheumatol. 2010;37:1188-94.
27. Segal B, Bowman SJ, Fox PC, et al. Primary Sjögren’s Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes. 2009;7:46.
28. Meijer JM, Meiners PM, Huddleston Slater JJ, et al. Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Rheumatology. 2009;48(9): 1077-82.
29. Aragona P, Di Stefano G, Ferreri F, Spinella R, Stilo A. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren’s syndrome patients. Br J Ophthalmol. 2002;86(8):879-84.
30. Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002;86(2):181-4.
31. Brignole F, Pisella PJ, Dupas B, Baeyens V, Baudouin C. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp Ophthalmol. 2005;243(6):531-8.
32. Condon PI, McEwen CG, Wright M, Mackintosh G, Prescott RJ, McDonald C. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br J Ophthalmol. 1999;83(10):1121-4.
33. McDonald CC, Kaye SB, Figueiredo FC, Macintosh G, Lockett C. A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond). 2002;16(5):601-7.
34. Toda I, Shinozaki N, Tsubota K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren’s syndrome. Cornea. 1996;15(2):120-8.
35. Papas AS, Sherrer YS, Charney M, et al. Successful treatment of dry mouth and dry eye symptoms in Sjögren’s syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J Clin Rheumatol. 2004;10(4):169-77.
36. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med. 1999;159(2): 174-81.
37. Wu CH, Hsieh SC, Lee KL, Li KJ, Lu MC, Yu CL. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren’s syndrome in Taiwan - a double-blind, placebo-controlled trial. J Formos Med Assoc. 2006;105(10):796-803.
38. Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med. 2002;162(11):1293-300.
39. Leung KC, McMillan AS, Wong MC, Leung WK, Mok MY, Lau CS. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren’s syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin Rheumatol. 2008;27(4):429-36.
40. Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren’s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004;138(1):6-17.
41. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002;46(3):748-54.
42. Voulgarelis M, Moutsopoulos HM. Malignant lymphoma in primary Sjögren’s syndrome. Isr Med Assoc J. 2001;3:761-6.
43. Kruszka P, O’Brian RJ. Diagnosis and management of Sjögren syndrome. Am Fam Physician. 2009;79(6):465-70.